AlveoGene

Activities: Research & Development

Trending Articles

  1. Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
  2. Therapeutic: ensifentrine for chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
  3. Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
  4. Bringing biotech to the Baltics: the rise of Lithuania Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
  5. Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA

Upcoming event

ISPE Singapore

28-30 August 2024 | Conference and exhibition | Singapore See all

Related Content

Research & Development

University funding propels new pharmaceutical company AlveoGene

AlveoGene has announced its launch following funding from universities and the securing of an exclusive licence to a proprietary and validated next-generation lentiviral delivery platform
Subscribe now